arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Invivyd, Inc.

IVVD
$0.92 ▼ -0.05 (-4.67%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
25 Visible periods
24 Metrics
Peer-ranked Benchmarks
Price Chart
24
Health
Poor
Bearish
auto_awesome

Analytical Summary

Invivyd, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $294.8M
Dividend Yield —
Revenue Growth 21.2% →
Op. Margin -320.8% ↘
ROIC -20.0% ↘
FCF / Share $-0.14 →
Trailing P/E —
Price / Book 1.5x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

25-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$14.29M
↑ +21.2% —
Net Income Profit after all expenses
$-41.40M
↓ -154.2% —
Operating Margin Operating profit as % of sales
-320.8%
↓ -2.2% 2th
FCF / Share Free cash flow per share
$-0.14
↑ +0.9% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
2
Returns ↑
27
Cash Quality ↑
70

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 6 years · 25 quarters